– USA, WI – NorthStar Medical Technologies, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals, announced the appointment of current Board member Jon Coulter as Non-Executive Chairman, succeeding Stephen Merrick, who is now retiring from that position.
About Jon Coulter
Jon Coulter has been a Board Member of NorthStar since 2010. He succeeds Mr. Stephen Merrick, who joined NorthStar in 2016, has served as Executive Chairman since July 2023 and is now retiring from that position.
Jon Coulter is Managing Director at Hendricks Holding Company, Inc. and has responsibility for several HHC portfolio companies, including NorthStar Medical Technologies LLC. Jon has served on NorthStar’s Board of Managers since 2010. Before joining HHC, Jon was an investment banker at Robert W. Baird & Co. and a Principal at Baird Capital Partners, the private equity arm of Baird. Jon was also an investment banker at Cleary Gull, Inc. Jon served twelve years in the U.S. Air Force as an Operations Staff Officer and Instructor Pilot, and is a veteran of Operation Desert Storm.
Jon Coulter earned a Bachelor of Science from Purdue University and an M.B.A. from the University of Wisconsin–Madison.
About NorthStar Medical Technologies, LLC
NorthStar Medical Technologies, based in Beloit, Wis., is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC.
NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces copper-67 (Cu-67) and is poised to be one of the first commercial-scale producers of non-carrier added actinium-225 (n.c.a. Ac-225). The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.
For more information: https://www.northstarnm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.